Your SlideShare is downloading. ×
0
3 Horrendous Health-Care
Stocks This Week
While the victors
celebrated in Sochi this
week, some Olympians felt
the agony of defeat. The
same was true in the world
o...
Onconova Therapeutics (Nasdaq: ONTX)
The stock of the biopharmaceutical firm focusing on cancer drugs
plunged nearly 38% f...
Why Onconova nosedived
• It announced disappointing results
for phase 3 study of rigosertib.
• Rigosertib failed to meet i...
Medbox (NasdaqOTH: MDBX)
Shares of this medical marijuana dispensing equipment maker
careened more than 24% this week.
Why Medbox shares got clobbered
• The company was the target of a
damaging online article by Citron
Research’s Andrew Left...
GW Pharmaceuticals (Nasdaq: GWPH)
The stock of the pharmaceutical firm focusing on medical
marijuana fell nearly 9% this w...
Why GW shares weren’t buzzing
• It was attacked by a short-seller,
Infitialis, in a blog post.
• The blogger listed multip...
Best shot at bouncing back?
• None of this week’s horrendous stocks
look very promising.
• Onconova still has a phase 2 st...
Find out which stock The Motley Fool’s chief
investment officer selected as the top pick for
2014 in our free report!
Upcoming SlideShare
Loading in...5
×

3 Horrendous Healthcare Stocks This Week 2-21-14

8,458

Published on

Which healthcare stocks were the worst of the worst this week?

Published in: Health & Medicine
0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
8,458
On Slideshare
0
From Embeds
0
Number of Embeds
9
Actions
Shares
0
Downloads
4
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-affymetrix-inc-shares-dropped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx
  • Transcript of "3 Horrendous Healthcare Stocks This Week 2-21-14"

    1. 1. 3 Horrendous Health-Care Stocks This Week
    2. 2. While the victors celebrated in Sochi this week, some Olympians felt the agony of defeat. The same was true in the world of health care. Source: Wikimedia Commons.
    3. 3. Onconova Therapeutics (Nasdaq: ONTX) The stock of the biopharmaceutical firm focusing on cancer drugs plunged nearly 38% for the week.
    4. 4. Why Onconova nosedived • It announced disappointing results for phase 3 study of rigosertib. • Rigosertib failed to meet its primary endpoint of median overall survival. • The study focused on use of the drug in the treatment of myelodysplastic syndrome, or MDS, in high-risk patients. • Another phase 2 study is under way for rigosertib in treating lower-risk MDS patients.
    5. 5. Medbox (NasdaqOTH: MDBX) Shares of this medical marijuana dispensing equipment maker careened more than 24% this week.
    6. 6. Why Medbox shares got clobbered • The company was the target of a damaging online article by Citron Research’s Andrew Left. • Left called Medbox’s stock “worthless” and accused the company of fraud. • Medbox publicly acknowledged some accounting errors that were corrected. • Medbox’s largest shareholder and chairman, Vincent Mehdizadeh, responded with a scathing criticism of Andrew Left.
    7. 7. GW Pharmaceuticals (Nasdaq: GWPH) The stock of the pharmaceutical firm focusing on medical marijuana fell nearly 9% this week.
    8. 8. Why GW shares weren’t buzzing • It was attacked by a short-seller, Infitialis, in a blog post. • The blogger listed multiple issues with GW Pharmaceuticals, including being overhyped as a marijuana play and overvalued. • The stock was hit hard initially, but recovered somewhat.
    9. 9. Best shot at bouncing back? • None of this week’s horrendous stocks look very promising. • Onconova still has a phase 2 study under way for rigersitib in treating lower-risk MDS, but it’s probably something of a long shot. • While short-sellers attacking Medbox and GW Pharmaceuticals don’t have the purest of motives, both stocks do appear to be overvalued. • Investors probably should consider looking elsewhere.
    10. 10. Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!
    1. A particular slide catching your eye?

      Clipping is a handy way to collect important slides you want to go back to later.

    ×